search
Back to results

Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitation

Primary Purpose

Hepatic Encephalopathy

Status
Recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Rehabilitation Training
Sponsored by
Chang Gung Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatic Encephalopathy focused on measuring Liver cirrhosis, Hepatic encephalopathy, Psychometric test, Sarcopenia, Fecal microbiota

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Patients with liver cirrhosis Exclusion Criteria: unstable vital sign such as shock, coma or intubation status Non-curative hepatocellular carcinoma (cannot receive operation, radiofrequency ablation, liver transplantation,etc Un-curative malignancies Poor-controlled diabetes mellitus (HbA1C≧8) Active alcoholism (male alcohol ≧40g/day, or ≧140g/week; female ≧ 30g/day, or ≧70g/week Psychiatric comorbidities Neurologic comorbidities like Alzheimer's, Parkinson's, stroke with neurological deficit Unable to speak Bed-ridden status Post- Liver transplantation.

Sites / Locations

  • Chang Gung Memorial HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Rehabilitation Training

No-Rehabilitation Training

Arm Description

Rehabilitation Training is provided to patients with Liver Cirrhosis combined with sarcopenia.

No extra training is provided to patients with Liver Cirrhosis combined with sarcopenia.

Outcomes

Primary Outcome Measures

Handgrip Strength
Handgrip strength is an assessment of muscle strength. The cutoff value of the handgrip is < 30 kg in men and < 20 kg in women.
Short Physical Performance Battery (SPPB)
Short Physical Performance Battery (SPPB) is an assessment of physical performance. The cut-off value of the Short Physical Performance Battery (SPPB) score for determining sarcopenia is ≤ 9.
Dual-energy X-ray absorptiometry (DEXA)
Dual-energy X-ray absorptiometry (DXA) is the gold-standard technique in the analysis of body composition. The cut-off value of appendicular skeletal muscle mass (ASMI) score for determining sarcopenia is < 7.0 kg/m^2 in men and < 5.4 kg/m^2 in women.
Mini-Mental Status Examination (MMSE)
Mini-Mental State Examination (MMSE) is one of the most commonly used methods in the assessment of cognitive mental status. The cut-off value of Mini-Mental State Examination (MMSE) score is < 28.
Psychometric Hepatic Encephalopathy Score (PHES)
The psychometric hepatic encephalopathy score (PHES) is the gold standard for diagnosing minimal hepatic encephalopathy (MHE). The cut-off value of the Psychometric Hepatic Encephalopathy Score (PHES) for determining minimal hepatic encephalopathy (MHE) is ≤ -4.
Animal Naming Test (ANT)
The animal naming test (ANT) is an easy tool for the assessment of hepatic encephalopathy (HE). The cut-off value of the Animal Naming Test (ANT) score for determining hepatic encephalopathy (HE) is ≤ 19.
Blood cytokine levels [IL-6]
Serum IL-6 level (pg/ mL)
Blood ammonia levels [NH3]
Serum ammonia level (μg/dL)
Electroencephalogram (EEG)
Quantified EEG spectral analysis: Grade 0: Mean dominant frequency (MDF)> 6.8 Hz and no theta nor delta wave Grade 1: MDF > 6.8Hz and theta wave relative power ≧35% Grade 2: MDF≤ 6.8 Hz and delta wave relative power<49% Grade 3: MDF≤ 6.8 Hz and delta wave relative power≧49%
Fecal Microbiota
Check fecal microbiota taxonomy profile and relative abundance changes.

Secondary Outcome Measures

Full Information

First Posted
August 8, 2023
Last Updated
September 10, 2023
Sponsor
Chang Gung Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT06040814
Brief Title
Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitation
Official Title
To Explore the Changes of Fecal Microbiota Before and After Treatment in Patients With Liver Cirrhosis Complicated With Hepatic Encephalopathy or Sarcopenia as a Reference for Future Fecal Microbiota Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2022 (Actual)
Primary Completion Date
November 30, 2025 (Anticipated)
Study Completion Date
November 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Through this plan, it will provide many benefits to patients with liver cirrhosis complicated with sarcopenia and/or hepatic encephalopathy, their family members, and the government in Taiwan: To explore the changes of fecal microbiota before and after treatment such as resistance training rehabilitation in patients with liver cirrhosis complicated with sarcopenia and/or hepatic encephalopathy as a reference for future fecal microbiota transplantation; To measure the changes of sarcopenia level before and after rehabilitation; To measure the changes of hepatic encephalopathy level before and after rehabilitation. These study results will certainly bring updated diagnostic tool, latest treatment options, avoid serious sequelae and reduce medical expenditure.
Detailed Description
Chronic liver disease is notorious as Taiwan's national disease and more than 4,000 patients died of liver cirrhosis each year in Taiwan. Hepatic encephalopathy (HE) manifests from minimal HE (MHE) to overt HE (OHE). The diagnosis of covert HE (CHE) requires psychometric tests or neurophysiological tools. However, psychometric testing for patients with CHE is often neglected in Taiwan. On the basis of the capability to detect all forms of HE, further investigation on the association of HE with fecal microbiota alterations is urgently needed. It is because HE is associated with dysregulation in the gut-liver-brain axis, which includes intestinal barrier dysfunction and gut microbial dysbiosis. However, despite current standard of care (SOC) therapy i.e., lactulose and rifaximin, there remains a subset of patients who continue to suffer recurrence, which leads to further cognitive impairment, sarcopenia and readmissions. There remain several factors that can influence the microbiota, such as demographics (geographic area, sex and diet), etiology, drugs, interventions, and finally the sampling compartment. These factors need to be controlled for and considered in the interpretation of future studies. The microbiome dynamic change during rehabilitation in cirrhotic patients with sarcopenia has never been studied and is worth exploring. Furthermore, from our previous study, the investigators have shown that one-year efficacy of rifaximin add-on to lactulose is superior to lactulose alone in patients with cirrhosis complicated with recurrent HE in Taiwan. The investigators also have preliminary data showing that rehabilitation could improve patient's sarcopenia. Further cohort validation is urgently required. Our innovative research purposes: To explore the changes of fecal microbiota before and after treatment such as resistance training rehabilitation as a reference for future fecal microbiota transplantation; To measure the changes of sarcopenia levels before and after rehabilitation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatic Encephalopathy
Keywords
Liver cirrhosis, Hepatic encephalopathy, Psychometric test, Sarcopenia, Fecal microbiota

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Rehabilitation Training
Arm Type
Experimental
Arm Description
Rehabilitation Training is provided to patients with Liver Cirrhosis combined with sarcopenia.
Arm Title
No-Rehabilitation Training
Arm Type
No Intervention
Arm Description
No extra training is provided to patients with Liver Cirrhosis combined with sarcopenia.
Intervention Type
Behavioral
Intervention Name(s)
Rehabilitation Training
Intervention Description
12 week Rehabilitation Training course
Primary Outcome Measure Information:
Title
Handgrip Strength
Description
Handgrip strength is an assessment of muscle strength. The cutoff value of the handgrip is < 30 kg in men and < 20 kg in women.
Time Frame
6 months
Title
Short Physical Performance Battery (SPPB)
Description
Short Physical Performance Battery (SPPB) is an assessment of physical performance. The cut-off value of the Short Physical Performance Battery (SPPB) score for determining sarcopenia is ≤ 9.
Time Frame
6 months
Title
Dual-energy X-ray absorptiometry (DEXA)
Description
Dual-energy X-ray absorptiometry (DXA) is the gold-standard technique in the analysis of body composition. The cut-off value of appendicular skeletal muscle mass (ASMI) score for determining sarcopenia is < 7.0 kg/m^2 in men and < 5.4 kg/m^2 in women.
Time Frame
6 months
Title
Mini-Mental Status Examination (MMSE)
Description
Mini-Mental State Examination (MMSE) is one of the most commonly used methods in the assessment of cognitive mental status. The cut-off value of Mini-Mental State Examination (MMSE) score is < 28.
Time Frame
6 months
Title
Psychometric Hepatic Encephalopathy Score (PHES)
Description
The psychometric hepatic encephalopathy score (PHES) is the gold standard for diagnosing minimal hepatic encephalopathy (MHE). The cut-off value of the Psychometric Hepatic Encephalopathy Score (PHES) for determining minimal hepatic encephalopathy (MHE) is ≤ -4.
Time Frame
6 months
Title
Animal Naming Test (ANT)
Description
The animal naming test (ANT) is an easy tool for the assessment of hepatic encephalopathy (HE). The cut-off value of the Animal Naming Test (ANT) score for determining hepatic encephalopathy (HE) is ≤ 19.
Time Frame
6 months
Title
Blood cytokine levels [IL-6]
Description
Serum IL-6 level (pg/ mL)
Time Frame
6 months
Title
Blood ammonia levels [NH3]
Description
Serum ammonia level (μg/dL)
Time Frame
6 months
Title
Electroencephalogram (EEG)
Description
Quantified EEG spectral analysis: Grade 0: Mean dominant frequency (MDF)> 6.8 Hz and no theta nor delta wave Grade 1: MDF > 6.8Hz and theta wave relative power ≧35% Grade 2: MDF≤ 6.8 Hz and delta wave relative power<49% Grade 3: MDF≤ 6.8 Hz and delta wave relative power≧49%
Time Frame
6 months
Title
Fecal Microbiota
Description
Check fecal microbiota taxonomy profile and relative abundance changes.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with liver cirrhosis Exclusion Criteria: unstable vital sign such as shock, coma or intubation status Non-curative hepatocellular carcinoma (cannot receive operation, radiofrequency ablation, liver transplantation,etc Un-curative malignancies Poor-controlled diabetes mellitus (HbA1C≧8) Active alcoholism (male alcohol ≧40g/day, or ≧140g/week; female ≧ 30g/day, or ≧70g/week Psychiatric comorbidities Neurologic comorbidities like Alzheimer's, Parkinson's, stroke with neurological deficit Unable to speak Bed-ridden status Post- Liver transplantation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
CHIEN-HAO HUANG, MD
Phone
+886 9753 66128
Email
q12248@cgmh.org.tw
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
CHIEN-HAO HUANG
Organizational Affiliation
Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chang Gung Memorial Hospital
City
Taoyuan
ZIP/Postal Code
333
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
CHIEN-HUNG CHEN, MD
Phone
+886 9753 66128
Email
q12248@cgmh.org.tw

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitation

We'll reach out to this number within 24 hrs